Van Karlyle Morris, M.D.

Peer-Reviewed Articles

1. Pattalachinti, V, Haque, E, Yousef, M, Yousef, A, Chowdhury, S, Overman, MJ, Parseghian, C, Morris, VK, Kee, BK, Huey, RW, Raghav, KS, Court, CM, Shen, JY. BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 39910160.
2. Lapelusa, M, Qiao, W, Iorgulescu, B, San Lucas, FA, Patel, KP, Bhamidipati, D, Thomas, J, You, YN, Foo, WC, Maru, D, Thirumurthi, S, Morris, VK, Kopetz, S, Overman, MJ, Ludford, K. Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40374594.
3. Elez, E, Yoshino, T, Shen, L, Lonardi, S, Van Cutsem, E, Eng, C, Kim, TW, Wasan, H, Desai, J, Ciardiello, F, Yaeger, R, Maughan, TS, Morris, VK, Wu, CS, Usari, T, Laliberté, RJ, Dychter, SS, Zhang, X, Tabernero, J, Kopetz, S. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer. New England Journal of Medicine 392(24):2425-2437, 2025. e-Pub 2025. PMID: 40444708.
4. Odisio, BC, Albuquerque, J, Lin, YM, Anderson, BM, OConnor, C, Rigaud, B, Briones-Dimayuga, M, Jones, AK, Fellman, B, Huang, SY, Kuban, JD, Metwalli, ZA, Sheth, RA, Habibollahi, P, Patel, MN, Shah, KY, Cox, V, Kang, HC, Morris, VK, Kopetz, S, Javle, M, Kaseb, A, Tzeng, CW, Cao, HT, Newhook, TE, Chun, YS, Vauthey, JN, Gupta, S, Paolucci, I, Brock, K. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL). The Lancet Gastroenterology and Hepatology 10(5):442-451, 2025. e-Pub 2025. PMID: 40090348.
5. Boda A, Bandey IN, Chowdhury S, Aggarwal S, Venugopala M, Fowlkes NW, Roszik J, Curran MA, Morris VK, Kopetz S, Singh M. IL-1R1 Blockade Boosts CD40 Agonist Immune Responses but Fails to Improve Efficacy or Reduce Hepatotoxicity in Pancreatic Cancer. bioRxiv, 2025. e-Pub 2025. PMID: 40060615.
6. Peddireddy AS, Huey R, Wolff RA, Lin K, Mitchell J, Scofield L, Jacob S, Nguyen DV, Rogers J, Portier S, Foo WC, Eng C, Morris VK. Clinicopathologic Features Associated with Survival for Immune Checkpoint Blockade in Patients with Metastatic Anal Cancer. Cancers (Basel) 17(6), 2025. e-Pub 2025. PMID: 40149273.
7. Ahmed, J, Knisely, A, Torrado, C, Stephen, B, Yang, Y, Song, J, Alshawa, A, Zarifa, A, Jhingran, A, Koay, EJ, Morris, VK, Javle, M, Wolff, RA, Meric-Bernstam, F, Pant, S, Rodon Ahnert, J, Naing, A. A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40139261.
8. Peddireddy, A, Huey, RW, Wolff, RA, Lin, K, Mitchell, J, Scofield, LC, Jacob, S, Nguyen, DV, Rogers, JE, Portier, S, Foo, WC, Eng, C, Morris, VK. Clinicopathologic Features Associated with Survival for Immune Checkpoint Blockade in Patients with Metastatic Anal Cancer. Cancers 17(6), 2025. e-Pub 2025. PMID: 40149273.
9. Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O'Hara MH, Eads J, King D, Shah MA, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA. Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group. JCO Precis Oncol 9:e2400489, 2025. e-Pub 2025. PMID: 40048671.
10. Morris VK, Liu S, Lin K, Zhu H, Prasad S, Mahvash A, Bhosale P, Sun B, Parra ER, Wistuba I, Peddireddy A, Yao J, Mendoza-Perez J, Knafl M, Woodman SE, Eng C, Halperin D. Phase II trial of atezolizumab and bevacizumab for treatment of HPV-positive unresectable or metastatic squamous cell carcinoma of the anal canal. Clin Cancer Res 31(9):1657-1666, 2025. e-Pub 2025. PMID: 40019482.
11. Morris, VK, Kennedy, EB, Amin, M, Aranha, O, Benson, AB, Dorth, JA, Horowitz, DP, Kennecke, HF, Kim, S, Kreppel, L, Mettu, NB, Rajdev, L, Riechelmann, R, Sio, TT, Eng, C. Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma. Journal of Clinical Oncology 43(5):605-615, 2025. e-Pub 2025. PMID: 39680825.
12. Alshenaifi JY, Vetere G, Maddalena G, Yousef M, White MG, Shen JP, Vilar E, Parseghian C, Dasari A, Morris VK, Huey R, Overman MJ, Wolff R, Raghav KP, Willis J, Alfaro K, Futreal A, You YN, Kopetz S. Mutational and co-mutational landscape of early onset colorectal cancer. Biomarkers 30(1):64-76, 2025. e-Pub 2025. PMID: 39761813.
13. Morris VK, Xiao W, Lin K, Wong CW, Wotman MT, Holliday EB, Huey RW, Noticewala SS, Ludmir EB, Bent AH, Ludford K, Messick C, Koay EJ, Smith G, Konishi T, Bednarski B, Chang GJ, Koong AC, You YN, Das P, Gillison ML. Time dependency for human papillomavirus circulating tumor DNA detection after chemoradiation as a prognostic biomarker for localized anal cancer. Clinical Cancer Research 31(12):2399-2405, 2025. e-Pub 2025. PMID: 39873618.
14. Bhamidipati, D, Johnson, JR, Lin, K, Pelicano, H, Eng, C, Huey, RW, Wolff, RA, Halperin, DM, Frumovitz, M, Wistuba, II, Duose, D, Mallampati, S, Luthra, R, Morris, VK. The Clinical Utility of a Next-Generation Sequencing-Based Approach to Detecting Circulating HPV DNA in Patients with Advanced Anal Cancer. Cancers 17(2), 2025. e-Pub 2025. PMID: 39858090.
15. Morris VK, Dorth JA, Kennedy EB, Eng C. Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline Clinical Insights. JCO Oncol Pract 21(5):609-612, 2024. e-Pub 2024. PMID: 39680814.
16. Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, Cusnir M, Dorth J, George M, Kachnic LA, Kennecke HF, Loree JM, Morris VK, Perez RO, Smith JJ, Strickland MR, Gholami S. Management of Locally Advanced Rectal Cancer: ASCO Guideline. Journal of Clinical Oncology 42(28):3355-3375, 2024. e-Pub 2024. PMID: 39116386.
17. Bhutiani N, Peacock O, Uppal A, Hu CY, Bednarski BK, Taggart MW, Dasari A, Morris VK, Kaur H, Kopetz S, Holliday EB, Das P, You YN, Chang GJ. The prognostic impact of tumor deposits in colorectal cancer: More than just N1c. Cancer, 2024. e-Pub 2024. PMID: 39306694.
18. Lee HM, Saw AK, Morris VK, Napolitano S, Bristow C, Srinivasan S, Peoples M, Sorokin A, Kanikarla Marie P, Schulz J, Singh AK, Terranova C, Coker O, Jain A, Kopetz S, Rai K. Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer. Clin Cancer Res 30(22):5166-5179, 2024. e-Pub 2024. PMID: 39269307.
19. Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncology 10(11), 2024. e-Pub 2024. PMID: 39264607.
20. Schrank, BR, Fuller, JA, Gallagher, CM, Morris, VK, Holliday, EB, Merriman, K, Nguyen, LH, Weaver, L, Nelson, K, Chiao, EY, Koong, A, Hawk, E, Chang, S. Institution-Wide Retreats Foster Organizational Learning and Action at a Comprehensive Cancer Center. Journal of Cancer Education 39(4):368-373, 2024. e-Pub 2024. PMID: 38468110.
21. Heath SG, Naughton JD, Magon NJ, Gray SG, Smith BR, Morris VK, Gobl C. Characterizing the amyloid core region of the tumor suppressor protein p16(INK4a) using a limited proteolysis and peptide-based approach. J Biol Chem 300(8):107590, 2024. e-Pub 2024. PMID: 39032649.
22. Wermke M, Holderried TAW, Luke JJ, Morris VK, Alsdorf WH, Wetzko K, Andersson BS, Wistuba II, Parra ER, Hossain MB, Grund-Groschke S, Aslan K, Satelli A, Marisetty A, Satam S, Kalra M, Hukelmann J, Kursunel MA, Pozo K, Acs A, Backert L, Baumeister M, Bunk S, Wagner C, Schoor O, Mohamed AS, Mayer-Mokler A, Hilf N, Krishna D, Walter S, Tsimberidou AM, Britten CM. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer 12(7), 2024. e-Pub 2024. PMID: 39038917.
23. Heath SG, Gray SG, Hamzah EM, O'Connor KM, Bozonet SM, Botha AD, de Cordovez P, Magon NJ, Naughton JD, Goldsmith DLW, Schwartfeger AJ, Sunde M, Buell AK, Morris VK, Gobl C. Amyloid formation and depolymerization of tumor suppressor p16(INK4a) are regulated by a thiol-dependent redox mechanism. Nat Commun 15(1):5535, 2024. e-Pub 2024. PMID: 38951545.
24. Antonoff, MB, Kui, N, Sun, R, Deboever, N, Hofstetter, WL, Mehran, RJ, Morris, VK, Rice, DC, Swisher, SG, Vaporciyan, AA, Walsh, GL, Rajaram, R. Factors associated with receipt of pulmonary metastasectomy in patients with lung-limited metastatic colorectal cancer. Journal of Thoracic and Cardiovascular Surgery 168(1):263-271, 2024. e-Pub 2024. PMID: 37690624.
25. Gilkes JM, Frampton RA, Board AJ, Hudson AO, Price TG, Morris VK, Crittenden DL, Muscroft-Taylor AC, Sheen CR, Smith GR, Dobson RCJ. A new lysine biosynthetic enzyme from a bacterial endosymbiont shaped by genetic drift and genome reduction. Protein Sci 33(7):e5083, 2024. e-Pub 2024. PMID: 38924211.
26. Arzola, A, Chang, E, Rooney, MK, Corrigan, KL, Das, P, Ludmir, EB, Koay, EJ, Minsky, B, Smith, GL, Messick, C, Morris, VK, Nebgen, D, Crane, C, Holliday, EB. Daily Vaginal Dilator Use During Radiation for Women With Squamous Cell Carcinoma of the Anus. Practical radiation oncology 14(2):e105-e116, 2024. e-Pub 2024. PMID: 37898354.
27. Deboever, N, Bayley, EM, Eisenberg, M, Hofstetter, WL, Mehran, RJ, Rice, DC, Rajaram, R, Roth, JA, Sepesi, B, Swisher, SG, Vaporciyan, AA, Walsh, GL, Bednarski, BK, Morris, VK, Antonoff, MB. Lung surveillance following colorectal cancer pulmonary metastasectomy. Journal of Thoracic and Cardiovascular Surgery 167(3):814-819.e2, 2024. e-Pub 2024. PMID: 37495170.
28. Damron, EP, McDonald, J, Rooney, MK, Das, P, Ludmir, EB, Minsky, B, Messick, C, Chang, GJ, Morris, VK, Holliday, EB. Salvage Treatment of Recurrent or Persistent Anal Squamous Cell Carcinoma. Clinical colorectal cancer 23(1):85-94, 2024. e-Pub 2024. PMID: 38216367.
29. Johnson, B, Morris, VK, Wang, X, Dasari, NV, Raghav, KS, Shen, JY, Lee, MS, Huey, RW, Parseghian, C, Willis, JA, Wolff, RA, Drusbosky, L, Overman, MJ, Kopetz, S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers 16(4), 2024. e-Pub 2024. PMID: 38398128.
30. Deboever, N, Bayley, EM, Eisenberg, M, Hofstetter, WL, Mehran, RJ, Rice, DC, Rajaram, R, Roth, JA, Sepesi, B, Swisher, SG, Vaporciyan, AA, Walsh, GL, Bednarski, BK, Morris, VK, Antonoff, MB. Do resected colorectal cancer patients need early chest imaging? Impact of clinicopathologic characteristics on time to development of pulmonary metastases. Journal of surgical oncology 129(2):331-337, 2024. e-Pub 2024. PMID: 37876311.
31. Singh, AP, Xiao, L, O’Brien, BJ, Blondeau, CE, Flowers, CR, Bruera, E, Morris, VK, Shah, AY. Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists. JCO Oncology Practice 20(1):137-144, 2024. e-Pub 2024. PMID: 37235818.
32. Simmons, K, Thomas, J, Ludford, K, Willis, JA, Serpas Higbie, V, Raghav, KS, Johnson, B, Dasari, NV, Kee, BK, Parseghian, C, Lee, MS, Le, PH, Morelli, MP, Shen, JY, Bent, AH, Vilar Sanchez, E, Wolff, RA, Kopetz, S, Overman, MJ, Morris, VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
33. Fox DA, Bhamidipati D, Konishi T, Kaur H, You N, Raghav KPS, Ge PS, Messick C, Johnson B, Morris VK, Thomas JV, Shah P, Bednarski BK, Kopetz S, Chang GJ, Ludford K, Higbie VS, Overman MJ. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer 194:113356, 2023. e-Pub 2023. PMID: 37827065.
34. Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
35. Rogers, JE, Sirisaengtaksin, A, Leung, M, Morris, VK, Xiao, L, Huey, RW, Wolff, RA, Eng, C, Vauthey, JN, Tzeng, CD, Johnson, B. Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal. Cancers 15(15), 2023. e-Pub 2023. PMID: 37568706.
36. Piha-Paul, SA, Tseng, C, Tran, HT, Gao, M, Karp, DD, Subbiah, V, Tsimberidou, AM, Kawedia, J, Fu, S, Pant, S, Yap, TA, Morris, VK, Kee, BK, Blum Murphy, M, Lim, J, Meric-Bernstam, F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer chemotherapy and pharmacology 92(2):107-118, 2023. e-Pub 2023. PMID: 37314501.
37. Tsimberidou, AM, Guenther, K, Andersson, BS, Mendrzyk, R, Alpert, A, Wagner, C, Nowak, A, Aslan, K, Satelli, A, Richter, F, Kuttruff-Coqui, S, Schoor, O, Fritsche, J, Coughlin, Z, Mohamed, A, Sieger, K, Norris, B, Ort, R, Beck, J, Vo, H, Hoffgaard, F, Ruh, M, Backert, L, Wistuba, II, Fuhrmann, D, Ibrahim, NK, Morris, VK, Kee, BK, Halperin, DM, Nogueras Gonzalez, G, Kebriaei, P, Shpall, E, Vining, D, Hwu, P, Singh, H, Reinhardt, C, Britten, CM, Hilf, N, Weinschenk, T, Maurer, D, Walter, S. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101). Cancer Immunology Research 11(7):925-945, 2023. e-Pub 2023. PMID: 37172100.
38. Morris, VK, Jazaeri, AA, Westin, SN, Pettaway, CA, George, S, Huey, RW, Grinsfelder, MO, Shafer, A, Johnson, B, Vining, D, Guo, M, Fellman, B, Frumovitz, M. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist 28(7):618-623, 2023. e-Pub 2023. PMID: 37104874.
39. Napolitano, S, Woods, M, Lee, HM, De Falco, V, Martini, G, Della Corte, CM, Martinelli, E, Famiglietti, V, Ciardiello, D, Anderson, A, Fowlkes, NW, Villareal, OE, Sorokin, A, Kanikarla Marie, P, Coker, O, Morris, VK, Altucci, L, Tabernero, J, Troiani, T, Ciardiello, F, Kopetz, S. Antitumor Efficacy of Dual Blockade with Encorafenib þ Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. Clinical Cancer Research 29(12):2299-2309, 2023. e-Pub 2023. PMID: 37040395.
40. Napolitano, S, Woods, M, Lee, HM, De Falco, V, Martini, G, Della Corte, CM, Martinelli, E, Famiglietti, V, Ciardiello, D, Anderson, A, Fowlkes, NW, Villareal, OE, Sorokin, A, Kanikarla Marie, P, Coker, O, Morris, VK, Altucci, L, Tabernero, J, Troiani, T, Ciardiello, F, Kopetz, S. Antitumor Efficacy of Dual Blockade with Encorafenib þ Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. Clinical Cancer Research 29(12):2299-2309, 2023. e-Pub 2023. PMID: 37040395.
41. Rooney MK, De B, Corrigan K, Smith GL, Taniguchi C, Minsky BD, Ludmir EB, Koay EJ, Das P, Koong AC, Peacock O, Chang G, You YN, Morris VK, Nogueras-González G, Holliday EB. Patient-reported Bowel Function and Bowel-related Quality of Life After Pelvic Radiation for Rectal Adenocarcinoma: The Impact of Radiation Fractionation and Surgical Resection. Clin Colorectal Cancer 22(2):211-221, 2023. e-Pub 2023. PMID: 36878805.
42. Kelly RJ, Bever K, Chao J, Ciombor KK, Eng C, Fakih M, Goyal L, Hubbard J, Iyer R, Kemberling HT, Krishnamurthi S, Ku G, Mordecai MM, Morris VK, Paulson AS, Peterson V, Shah MA, Le DT. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. J Immunother Cancer 11(6), 2023. e-Pub 2023. PMID: 37286304.
43. Bozonet SM, Magon NJ, Schwartfeger AJ, Konigstorfer A, Heath SG, Vissers MCM, Morris VK, Gobl C, Murphy JM, Salvesen GS, Hampton MB. Oxidation of caspase-8 by hypothiocyanous acid enables TNF-mediated necroptosis. J Biol Chem 299(6):104792, 2023. e-Pub 2023. PMID: 37150321.
44. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg 277(5):813-820, 2023. e-Pub 2022. PMID: 35797554.
45. Tabernero J, Van Cutsem E, Garralda E, Tai D, De Braud F, Geva R, van Bussel MTJ, Fiorella Dotti K, Elez E, de Miguel MJ, Litwiler K, Murphy D, Edwards M, Morris VK. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. Oncologist 28(3):230-238, 2023. e-Pub 2023. PMID: 36811382.
46. Hernandez, S, Das, P, Holliday, EB, Shen, L, Lu, W, Johnson, B, Messick, C, Taniguchi, C, Skibber, JM, Ludmir, EB, You, YN, Smith, GL, Bednarski, BK, Kostousov, L, Koay, EJ, Minsky, B, Tillman, MM, Portier, S, Eng, C, Koong, A, Chang, GJ, Foo, WC, Wang, J, Solis Soto, LM, Morris, VK. Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers 15(6), 2023. e-Pub 2023. PMID: 36980587.
47. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
48. Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 41(3):101200JCO2201423, 2023. e-Pub 2023. PMID: 36351210.
49. Morris VK, Kennedy EB, Baxter NN, Benson AB, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, Fakih MG, Gholami S, Hong TS, Jaiyesimi I, Klute K, Lieu C, Sanoff H, Strickler JH, White S, Willis JA, Eng C. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol 41(3):JCO2201690, 2023. e-Pub 2023. PMID: 36252154.
50. Elnaggar JH, Huynh VO, Lin D, Hillman RT, Abana CO, El Alam MB, Tomasic KC, Karpinets TV, Kouzy R, Phan JL, Wargo J, Holliday EB, Das P, Mezzari MP, Ajami NJ, Lynn EJ, Minsky BD, Morris VK, Milbourne A, Messick CA, Klopp AH, Futreal PA, Taniguchi CM, Schmeler KM, Colbert LE. HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development. Front Immunol 14:1051431, 2023. e-Pub 2023. PMID: 37063829.
51. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. e-Pub 2022. PMID: 35946836.
52. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
53. Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6. Cancer Res 82(18):3335-3344, 2022. e-Pub 2022. PMID: 35913398.
54. De B, Corrigan KL, Rooney MK, Ludmir EB, Das P, Smith GL, Taniguchi CM, Minsky BD, Koay EJ, Koong A, Morris VK, Messick CA, You YN, Chang GJ, Westney OL, Nogueras Gonzalez GM, Holliday EB. Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys 114(1):78-88, 2022. e-Pub 2022. PMID: 35589011.
55. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
56. Lin D, El Alam MB, Jaoude JA, Kouzy R, Phan JL, Elnaggar JH, Resendiz B, Medrano AYD, Lynn EJ, Nguyen ND, Noticewala SS, Mathew GG, Holliday EB, Minsky BD, Das P, Morris VK, Eng C, Mezzari MP, Petrosino JF, Ajami NJ, Klopp AH, Taniguchi CM, Colbert LE. Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. Int J Radiat Oncol Biol Phys 113(5):974-984, 2022. e-Pub 2022. PMID: 35513187.
57. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
58. Rogers JE, Woodard TL, Gonzalez GM, Dasari A, Johnson B, Morris VK, Kee B, Vilar E, Nancy You Y, Chang GJ, Bednarski B, Skibber JM, Rodriguez-Bigas MA, Eng C. Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstet Med 15(2):118-124, 2022. e-Pub 2022. PMID: 35845232.
59. Morris VK, Kopetz S. Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. Nat Rev Cancer 22(6):317-318, 2022. e-Pub 2022. PMID: 35277674.
60. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. e-Pub 2022. PMID: 35557581.
61. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer 21(1):e28-e37, 2022. e-Pub 2022. PMID: 34794903.
62. Holliday EB, Morris VK, Johnson B, Eng C, Ludmir EB, Das P, Minsky BD, Taniguchi C, Smith GL, Koay EJ, Koong AC, Delclos ME, Skibber JM, Rodriguez-Bigas MA, You YN, Bednarski BK, Tillman MM, Chang GJ, Jennings K, Messick CA. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist 27(1):40-47, 2022. e-Pub 2022. PMID: 35305097.
63. Morris VK, George TJ. Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?. Clin Cancer Res 28(3):438-440, 2022. e-Pub 2022. PMID: 34848532.
64. Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
65. Corrigan KL, Rooney MK, De B, Ludmir ED, Das P, Smith GL, Taniguchi C, Minsky BD, Koay EJ, Koong A, Morris VK, Messick CA, Nogueras-Gonzalez G, Holliday EB. Patient-reported sexual function in long-term survivors of anal cancer treated with definitive intensity-modulated radiotherapy and concurrent chemotherapy. Pract Radiat Oncol 12(5):e397-e405, 2022. e-Pub 2022. PMID: 35643295.
66. De B, Ludmir EB, Messick CA, Cagley MC, Morris VK, Das P, Minsky BD, Taniguchi CM, Smith GL, Koay EJ, Koong AC, Mohan R, Holliday EB. Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. J Gastrointest Oncol 12(5):2412-2422, 2021. e-Pub 2021. PMID: 34790402.
67. Verbus EA, Rossi AJ, Luna AJ, Iqbal A, Morris VK, Hernandez JM. Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA). Ann Surg Oncol 28(8):4095-4097, 2021. e-Pub 2021. PMID: 33999346.
68. Wiggins CJ, Morris VK, Klimas NK, Nagarajan P, Curry JL, Richards KN. Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1. JAAD Case Rep 13:23-25, 2021. e-Pub 2021. PMID: 34136620.
69. Antonoff MB, Morris VK. Reply: Biology is king, but metastasectomy still has a role for properly selected patients. J Thorac Cardiovasc Surg 162(1):e136-e138, 2021. e-Pub 2021. PMID: 33419552.
70. Corsini EM, Mitchell KG, Correa A, Morris VK, Antonoff MB, MD Anderson Pulmonary Metastasectomy Working Group MD. Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy. J Thorac Cardiovasc Surg 162(1):296-305, 2021. e-Pub 2021. PMID: 32713636.
71. Advani, S, Swartz, MD, Loree, JM, Davis, JS, Sarsashek, AM, Lam, MC, Lee, MS, Bressler, J, Lopez, DS, Daniel-MacDougall, CR, Morris, VK, Shureqi, I, Kee, BK, Dasari, NV, Vilar Sanchez, E, Overman, MJ, Hamilton, SR, Maru, DM, Braithwaite, D, Kopetz, S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical colorectal cancer 20(2):137-147.e1, 2021. e-Pub 2021. PMID: 33229221.
72. Kanikarla Marie, P, Haymaker, CL, Parra Cuentas, ER, Kim, YU, Segura Lazcano, R, Gite, S, Lorenzini, D, Wistuba, II, Tidwell, R, Song, X, Foo, WC, Maru, DM, Chun, YS, Futreal, A, Kee, BK, Menter, DG, Solis Soto, LM, Tzeng, CD, Parseghian, C, Raghav, KS, Morris, VK, Chang, C, Jenq, RR, Tam, AL, Bernatchez, C, Kopetz, S, Vauthey, JN, Overman, MJ. Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases. Clinical Cancer Research 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
73. Hester R, Advani S, Rashid A, Holliday E, Messick C, Das P, You YN, Taniguchi C, Koay EJ, Bednarski B, Rodriguez-Bigas M, Skibber J, Wolff R, Chang GJ, Minsky BD, Foo WC, Rothschild N, Morris VK, Eng C. CEA as a blood-based biomarker in anal cancer. Oncotarget 12(11):1037-1045, 2021. e-Pub 2021. PMID: 34084278.
74. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol 39(4):285-294, 2021. e-Pub 2021. PMID: 33356422.
75. Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Andre T. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. J Natl Cancer Inst 113(2):208-211, 2021. e-Pub 2021. PMID: 32294214.
76. Morris VK, Strickler JH. Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annu Rev Med 72:399-413, 2021. e-Pub 2021. PMID: 33502901.
77. Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res 27(1):120-130, 2021. e-Pub 2021. PMID: 33109741.
78. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5:613-621, 2021. e-Pub 2021. PMID: 34250391.
79. Dos Anjos Jácome, AA, Kee, BK, Fogelman, D, Dasari, NV, Shureiqi, I, Raghav, KS, Morris, VK, Johnson, B, Overman, MJ, Wolff, RA, Kopetz, S, Rogers, JE, Ahmed, S, Mehdizadeh, A, Rothschild, ND, Eng, C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer. Clinical colorectal cancer 19(4):248-255.e6, 2020. e-Pub 2020. PMID: 32665092.
80. Jácome AA, Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, VK M, Johnson B, Rothschild ND, Wolff RA, Eng C. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer 19(4):e189-e199, 2020. e-Pub 2020. PMID: 32680816.
81. Saleh M, Cassier PA, Eberst L, Naik G, Morris VK, Pant S, Terret C, Gao L, Long A, Mao H, McNeely S, Wagner EK, Carlesi RM, Fu S. Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. Oncologist 25(11):e1628-e1639, 2020. e-Pub 2020. PMID: 32537847.
82. Rogers JE, Jácome AAA, Ohinata A, Wolff R, Morris VK, Johnson B, Mehdizadeh A, Rothschild ND, Ahmed SU, Guerra JL, Eng C. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Rev Anticancer Ther 20(10):1-8, 2020. e-Pub 2020. PMID: 32799569.
83. Morris VK, Bekaii-Saab T. Improvements in Clinical Outcomes for BRAFV600E-mutant Metastatic Colorectal Cancer. Clin Cancer Res 26(17):4435-4441, 2020. e-Pub 2020. PMID: 32253230.
84. Chu JE, Johnson B, Kugathasan L, Morris VK, Raghav K, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Kopetz S, Schaeffer DF, Loree JM. Population-based screening for BRAFV600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis. Clin Cancer Res 26(17):4599-4605, 2020. e-Pub 2020. PMID: 32571791.
85. Corsini EM, Datar SS, Mitchell KG, Zhou N, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Blackmon SH, Loree JM, VK M, Antonoff MB. High mutational concordance between primary colorectal tumors and associated pulmonary metastases. J Surg Oncol 121(6):984-989, 2020. e-Pub 2020. PMID: 32077113.
86. Eng, C, Fakih, MG, Amin, M, Morris, VK, Hochster, HS, Boland, P, Uronis, HE. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget 11(15):1334-1343, 2020. e-Pub 2020. PMID: 32341753.
87. Advani, S, Shi, Q, Overman, MJ, Loree, JM, Lam, MC, Morris, VK, Shureiqi, I, Kee, BK, Dasari, NV, Vilar Sanchez, E, Sarshekeh, AM, Lin, HK, Manuel, S, Hamilton, SR, Raghav, KS, Maru, DM, Kopetz, S, Wang, XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clinical colorectal cancer 19(1):48-56.e2, 2020. e-Pub 2020. PMID: 32008976.
88. Chen E, Abu-Sbeih H, Thirumurthi S, Mallepally N, Khurana S, Wei D, Altan M, VK M, Tan D, Barcenas CH, Wang Y. Clinical characteristics of colitis induced by taxane-based chemotherapy. Ann Gastroenterol 33(1):59-67, 2020. e-Pub 2020. PMID: 31892799.
89. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, VK M, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 381(17):1632-1643, 2019. e-Pub 2019. PMID: 31566309.
90. Clifton K, Rich TA, Parseghian C, Raymond VM, Dasari A, Pereira AA, Willis J, Loree JM, Bauer TM, Chae YK, Sherrill G, Fanta P, Grothey A, Hendifar A, Henry D, Mahadevan D, Nezami M, Tan B, Wainberg ZA, Lanman R, Kopetz S, Morris VK. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precision Oncology, 2019. e-Pub 2019.
91. Korphaisarn, K, Morris, VK, Davis, JS, Overman, MJ, Fogelman, D, Kee, BK, Dasari, NV, Raghav, KS, Shureiqi, I, Trupti, M, Wolff, RA, Eng, C, Menter, DG, Hamilton, SR, Kopetz, S. Signet ring cell colorectal cancer. British journal of cancer 121(6):505-510, 2019. e-Pub 2019. PMID: 31406299.
92. Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Hofstetter WL, Vaporciyan AA, VK M, Antonoff MB. Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. J Surg Oncol 120(4):729-735, 2019. e-Pub 2019. PMID: 31290159.
93. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, VK M, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer 125(12):2002-2010, 2019. e-Pub 2019. PMID: 30854646.
94. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol 30(2):243-249, 2019. e-Pub 2018. PMID: 30462160.
95. Johnson, B, Loree, JM, Dos Anjos Jácome, AA, Mendis, S, Syed, M, Morris, VK, Parseghian, C, Dasari, NV, Pant, S, Raymond, VM, Vilar Sanchez, E, Overman, MJ, Kee, BK, Eng, C, Raghav, KS, Kopetz, S. Atypical, non-V600 BRAF mutations as a potential mechanism of resistance to EGFR inhibition in metastatic colorectal cancer. JCO Precision Oncology 3:1-10, 2019. e-Pub 2019. PMID: 32914034.
96. Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer 17(4):e699-e709, 2018. e-Pub 2018. PMID: 30205948.
97. Rich, TA, Clifton, K, Grothey, A, Hendifar, A, Henry, D, Kagawa, Y, Nakamura, Y, Okamoto, W, Tan, BR, Sherrill, GB, Yoshino, T, Raymond, VM, Shiotsu, Y, Lanman, RB, Morris, VK. RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 29:viii162, 2018. e-Pub 2018. PMID: 32136282.
98. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, VK M, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2018. PMID: 29180604.
99. V M, Rao X, Pickering C, Foo WC, Rashid A, Eterovic K, Kim T, Chen K, Wang J, Shaw K, Eng C. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res 15(11):1542-1550, 2017. e-Pub 2017. PMID: 28784613.
100. Lima Pereira, AA, Morelli, MP, Overman, MJ, Kee, BK, Fogelman, D, Vilar Sanchez, E, Shureiqi, I, Raghav, KS, Eng, C, Manuel, S, Crosby, S, Wolff, RA, Banks, K, Lanman, RB, Talasaz, AA, Kopetz, S, Morris, VK. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PloS one 12(8), 2017. e-Pub 2017. PMID: 28850629.
101. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
102. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-453, 2017. e-Pub 2017. PMID: 28223062.
103. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 28(3):642-650, 2017. e-Pub 2017. PMID: 27993791.
104. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
105. Overman MJ, Morris, VK, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
106. Raghav K, Morris VK, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget 7(34):54627-54631, 2016. e-Pub 2016. PMID: 27421137.
107. Overman MJ, Morris, VK, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget 7(41):67495-67506, 2016. e-Pub 2016. PMID: 27542211.
108. Jauch SF, Morris VK, Jensen CT, Kaseb AO. Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. Pancreatology 16(1):153-6, 2016. e-Pub 2016. PMID: 26456669.
109. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris VK, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 33(34):4032-8, 2015. e-Pub 2015. PMID: 26460303.
110. Morris VK, Rashid A, Rodriguez-Bigas M, Das P, Chang G, Ohinata A, Rogers J, Crane C, Wolff RA, Eng C. Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist 20(11):1247-52, 2015. e-Pub 2015. PMID: 26382740.
111. Pereira AA, Rego JF, Morris VK, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2015. PMID: 25535726.
112. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
113. Morris VK, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
114. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14(1):660, 2014. e-Pub 2014. PMID: 25208577.
115. Morris VK, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep 5:11, 2013. e-Pub 2013. PMID: 23585929.
116. Jabbour E, Morris VK, Kantarjian H, Yin CC, Burton E, Cortes J. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 120(16):3382-3, 2012. e-Pub 2012. PMID: 23086624.
117. Morris VK, Spraker HL, Howard SC, Ware RE, Reiss UM. Severe thrombocytopenia with iron deficiency anemia. Pediatr Hematol Oncol 27(5):413-9, 2010. e-Pub 2010. PMID: 20670168.
118. Morris VK, Izard T. Substrate-induced asymmetry and channel closure revealed by the apoenzyme structure of Mycobacterium tuberculosis phosphopantetheine adenylyltransferase. Protein Sci 13(9):2547-52, 2004. e-Pub 2004. PMID: 15322293.
119. Brown KL, Morris VK, Izard T. Rhombohedral crystals of Mycobacterium tuberculosis phosphopantetheine adenylyltransferase. Acta Crystallogr D Biol Crystallogr 60(Pt 1):195-6, 2004. e-Pub 2004. PMID: 14684928.

Invited Articles

1. Morris V, Kopetz S. Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. Nature Reviews Cancer, 2022. e-Pub 2022.
2. Morris V, Dasari A, Kopetz S. Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncol 5(8):1101-1103, 2019. e-Pub 2019. PMID: 31070713.
3. VK M. Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Curr Colorectal Cancer Rep 15(2):53-60, 2019. e-Pub 2019. PMID: 31762713.
4. Morris VK, Eng C. Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. J Natl Compr Canc Netw 16(7):903-908, 2018. e-Pub 2018. PMID: 30006430.

Review Articles

1. Singh, M, Morris, VK, Bandey, I, Hong, DS, Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends in Cancer 10(7):598-609, 2024. e-Pub 2024. PMID: 38821852.
2. Elez, E, Kopetz, S, Tabernero, J, Bekaii-Saab, T, Taieb, J, Yoshino, T, Manji, G, Fernandez, KC, Abbattista, A, Zhang, X, Morris, VK. SEAMARK. Future oncology (London, England) 20(11):653-663, 2024. e-Pub 2024. PMID: 37815847.
3. Holliday, EB, Peddireddy, A, Morris, VK. Prognostic and Predictive Markers for Patients With Anal Cancer. JNCCN Journal of the National Comprehensive Cancer Network 21(6):678-684, 2023. e-Pub 2023. PMID: 37308122.
4. Eng C, Ciombor KK, Cho M, Dorth JA, Rajdev LN, Horowitz DP, Gollub MJ, Jácome AA, Lockney NA, Muldoon RL, Washington MK, O'Brian BA, Benny A, Lebeck Lee CM, Benson AB, Goodman KA, Morris VK. Anal Cancer: Emerging Standards in a Rare Rare Disease. J Clin Oncol 40(24):JCO2102566, 2022. e-Pub 2022. PMID: 35649196.
5. Jácome AA, Morris VK, Eng C. The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. Curr Treat Options Oncol 23(8):1073-1085, 2022. e-Pub 2022. PMID: 35666353.
6. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. e-Pub 2022. PMID: 35608860.
7. Tsimberidou, AM, Morris, VK, Vo, H, Eck, S, Lin, YF, Rivas, JM, Andersson, BS. T-cell receptor-based therapy. Journal of Hematology and Oncology 14(1), 2021. e-Pub 2021. PMID: 34193217.
8. Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol 11:643815, 2021. e-Pub 2021. PMID: 34367949.
9. Dasari A, VK M, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17(12):757-770, 2020. e-Pub 2020. PMID: 32632268.
10. Lee HM, Morris V, Napolitano S, Kopetz S. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer. Oncology (Williston Park) 33(6):206-11, 2019. e-Pub 2019. PMID: 31219603.
11. Morris, VK, Eng, C. Metastatic Anal Cancer and Novel Agents. Surgical oncology clinics of North America 26(1):133-142, 2017. e-Pub 2017. PMID: 27889032.
12. Morris V, Eng C. Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. J Gastrointest Oncol 7(5):721-726, 2016. e-Pub 2016. PMID: 27747086.
13. Morris, VK, Qiao, W, Kopetz, S. BRAF Mutations in Non-Metastatic Colorectal Cancer. Current Colorectal Cancer Reports 11(6):303-310, 2015. e-Pub 2015.
14. Morris VK, Kopetz S. Clinical biomarkers in colorectal cancer. Clin Adv Hematol Oncol 11(12):768-76, 2013. e-Pub 2013. PMID: 24893280.

Editorials

1. VK M, George TJ. Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?. Clinical Cancer Research 28:438-440, 2022.
2. Noticewala SS, Ludmir EB, Eng C, Holliday EB, Minsky BD, Morris VK, Das P. Anal Cancer Treatment Regimen Considerations for the COVID-19 Era: In Regard to Tchelebi et al. Radiother Oncol 151:56-57, 2020. PMID: 32710989.
3. Morris VK. Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral. Clin Cancer Res 25(7):2030-2032, 2019. PMID: 30655314.

Abstracts

1. VK M, Liu S, Johnson B, Prasad S, Mahvash A, Bhosale P, Rubin L, Rothschild N, Futreal A, Wistuba I, Hwu P, Yao J, Eng C, Halperin D. Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer. ESMO Annual Meeting, 2020. e-Pub 2020.
2. VK M, Kee BK, Overman MJ, Fogelman DR, Dasari A, Raghav KS, Shureiqi I, Johnson B, Parseghian CM, Wolff RA, Eng C, Garg N, Kopetz S. Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers. ASCO Annual Meeting 38:(suppl; abstr 4047), 2020. e-Pub 2020.
3. Sarshekeh AM, Lam M, Zorrilla IR, Holliday EB, Das P, Kee BK, Overman MJ, Parseghian CM, Shen JP, Tam A, Cuentas ERP, Zhang L, Wang X, Duose DY, Luthra R, Reddy N, Maru DM, Kopetz S, VK M. Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: A phase II trial of bintrafusp alfa in CMS4 metastatic CRC. ASCO Annual Meeting 38:(suppl; abstr 4084), 2020. e-Pub 2020.
4. Johnson B, Thomas JV, Dasari A, Raghav KPS, Sanchez EV, Kee BK, Eng C, Parseghian CM, VK M, Wolff RA, Shureiqi I, Kopetz S, Overman MJ. A phase II study of durvalumab (MEDI4736) (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). ASCO Gastrointestinal Cancer Symposium 38, 2020. e-Pub 2020.
5. Parseghian CM, Willis J, VK M, Raghav KPS, Dasari A, Raymond VM, Lanman RB, Overman MJ, Kopetz S. Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure. ASCO Annual Meeting, 2019. e-Pub 2019.
6. Chu JE, Johnson B, VK M, Raghav KPS, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Schaeffer DF, Kopetz S, Loree JM. Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis. ASCO Annual Meeting, 2019. e-Pub 2019.
7. Rich TA, Clifton K, Raymond VM, Dasari A, Raghav KPS, Parseghian CM, Lanman RB, Kopetz S, VK . Association between gene fusions and anti-EGFR resistance signature in colorectal cancer. ASCO Annual Meeting, 2019. e-Pub 2019.
8. Johnson B, Loree JM, VK M, Dasari A, Pant S, Raghav KPS, Kopetz S. Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer. ASCO Gastrointestinal Cancer Symposium, 2019. e-Pub 2019.
9. Nusrat M, Oh J, Jiang ZQ, Dasari A, Fogelman DR, Kee BK, Menter D, Raghav KPS, VK M, Wu J, Meric-Bernstam F, Morris J, Overman MJ, Kopetz S. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. ASCO Annual Meeting, 2018. e-Pub 2018.
10. Clifton K, Raymond VM, Dasari A, Raghav KPS, Parseghian CM, Pereira AA, Loree JM, Yaeger R, Strickler JH, Corcoran RB, Lanman R, Kopetz S, VK M. Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay. ASCO Annual Meeting, 2018. e-Pub 2018.
11. Kopetz S, McDonough SL, VK M, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, Wang SE, Lieu C, Eckhardt G, Semrad TJ, Kaberle K, Guthrie KA, Hochster HS. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). ASCO Gastrointestinal Cancer Symposium, 2017. e-Pub 2017.
12. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou A, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase 1B Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation. ASCO Annual Meeting 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
13. Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, VK M, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. ASCO Annual Meeting 114(12):1352-61, 2016. e-Pub 2016. PMID: 27272216.
14. VK M, Ciombor KK, Salem ME, Nimeiri HS, Iqbal S, Singh PP, Polite BN, Deming DA, Chan E, Wade JL, Bekaii-Saab TS, Uronis HE, Pasia MG, Bland G, Wolff RA, Ohinata A, Ohaji C, Rogers J, Sharma P, Eng C. NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). ASCO Annual Meeting, 2016. e-Pub 2016.
15. VK M, Mahvash A, Vence L, Blando J, Wolff RA, Ohinata A, Ohaji C, Allison JA, Sharma P, Eng C. NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response. AACR Annual Meeting, 2016. e-Pub 2016.
16. Sorokin A, Bitner L, Wu J, Menter D, Kopetz S, Morris. Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer. ASCO Gastrointestinal Cancer Symposium, 2016. e-Pub 2016.
17. VK M, Wu J, Adam L, Tian F, Gagea M, Hong DS, Menter D, Kopetz S. Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer. ASCO Gastrointestinal Cancer Symposium, 2016. e-Pub 2016.
18. Morris VK. Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2015. e-Pub 2015.
19. Morris VK, Rashid A, Rodriguez-Bigas M, Das P, Chang G, Ohinata A, Rogers J, Crane C, Wolff RA, Eng C. Clinicopathologic Features Associated with Human Papillomavirus/p16 in Patients with Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist 20(11):1247-52, 2015. e-Pub 2015. PMID: 26382740.
20. Janku S, Huang H, Fujii T, Shelton D, Madwani K, Fu S, Tsimberidou A, Piha-Paul S, Wheler J, Zinner R, Naing A, Hong D, Karp D, Cabrilo G, Kopetz S, Subbiah V, Luthra R, Kee B, Eng C, Morris VK, Karlin-Neumann G, Meric-Bernstam F. Multiplex KRASG12/G13 Mutation Testing of Unamplified. Annal of Oncology 75(15), 2015. e-Pub 2015.
21. Morris VK, Morelli MP, Janku F, Overman MJ, Kee BK, Fogelman DR, Vilar Sanchez E, Shureiqi I, Garrett CR, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Burnham Lanman R, Talasaz AA, Kopetz S. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. J Clin Oncology 33, 2015. e-Pub 2015.
22. VK M, Morelli MP, Janku F, Overman MJ, Kee BK, Fogelman DR, Sanchez EV, Shureiqi I, Garrett CR, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. ASCO Annual Meeting, 2015. e-Pub 2015.
23. Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients. J Clin Oncology 33, 2015. e-Pub 2015.
24. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
25. Morris V, James B, Tian F, Jiang ZQ, Overman M, Maru D, Menter D, Powis G, Kopetz S. Acquired Mutations in MAPK Signaling Pathway Following Initial Pharmacological Response in BRAF-mutated Metastatic Colorectal Cancer (mCRC). J Clin Oncology 33(3), 2015. e-Pub 2015.
26. Morris VK, Overman MJ, Eng C, Vilar-Sanchez E, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Kopetz S. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). J Clin Oncology 33(3), 2015. e-Pub 2015.
27. Morris VK, Overman MJ, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. J Clin Oncology 31(4), 2014. e-Pub 2014.
28. Hong DS, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, Zinner R, Fogelman DR, R Mistry R, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers. J Clin Oncology 32, 2014. e-Pub 2014.
29. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. J Clin Oncology 32, 2014. e-Pub 2014.
30. Morris VK, Rashid A, Rodriguez-Bigas MA, Das P, Wolff RA, Chang GJ, Crane CH, Phillips J, Ohinata A, Rogers J, Eng C. Association of human papillomavirus with unique clinicopathologic features in patients with metastatic squamous cell carcinoma of the anal canal. J Clin Oncology 32(3), 2014. e-Pub 2014.
31. Morris VK, Overman MJ, Eng C, Vilar-Sanchez E, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Kopetz S. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. J Clin Oncology 31, 2013. e-Pub 2013.
32. Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Kopetz S, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. J Clin Oncology 30, 2012. e-Pub 2012.
33. Soliman PT, VK M, Sun CC, Bodurka DC. No increase in risk associated with primary surgical cytoreduction in women diagnosed with ovarian cancer at an advanced age. International Journal of Gynecological Cancer 16(3):685, 2006. e-Pub 2006.

Book Chapters

1. Yeung, ZP, Mistry, T, Morris, VK. Anal Carcinoma, 153-160, 2024.
2. Tan, CH, Morris, VK, Das, P, Rodriguez-Bigas, MA, Iyer, RB. Colorectal Cancer, 268-284, 2022.
3. Morris, VK. Adjuvant Systemic Chemotherapy, 301-308, 2022.
4. Yeung Z, Mistry T, VK M. Anal Carcinoma. In: Diagnosis and Management Guide for Anorectal Disease: A Clinical Reference, 2019.
5. Morris VK. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology 3rd edition, 2016.
6. Morris VK. Anal Cancer. In: The MD Anderson Manual of Medical Oncology 3rd edition, 2016.